Moreover, we analyzed the relationship between EpCAM mRNA expression with clinical-pathological parameters of PCa patients by UALCAN, including patients’ gleason score, molecular signature, nodal metastasis, and TP53 mutation status. The gene discussed is TP53; the disease is posterior cortical atrophy.